Drug Trial Radar · NCT01704781
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Last checked: Nov 19, 2026Latest source record: Mar 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Sep 2012
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Bionor Immuno ASIndustry
- Sponsor type
- Industry
- Collaborators
- Celgene Corporation
- First posted
- Oct 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency. Vacc-4x is a peptide-based HIV immunotherapy and the primary objective is to strengthen the immune system's response to HIV p24. By adding Lenalidomide, an immunomodulatory agent, as a supporting drug, it is anticipated that the effect of Vacc-4x might be enhanced.
Conditions
- HIV-1 Infection
Interventions
LenalidomideDrug
In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
Lenalidomide placeboDrug
Capsules are identical to the active Lenalidomide capsules used.
Vacc-4XDrug
Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
rhuGM-CSFDrug
Granulocyte macrophage colony stimulating factor as a local adjuvant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting ToxicityTime frame: 31 days
- Part A: To Establish Highest Tolerated Dose of Lenalidomide, CD4 Counts Over TimeTime frame: 31 days
- Part B: Change in CD4 CountTime frame: Week 26
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Klinik I für Innere Medizin Klinikum Der Universität zu Köln
Cologne, Germany
University Medical Center Hamburg-Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, Germany
EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125
Berlin, State of Berlin, Germany
Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1
Berlin, State of Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.